The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials

Table 2

Subgroup analysis results of peripheral blood T lymphocytes.

Subgroups	SM	CD3^+ T cells				CD3^+ CD4^+ T cells				CD3^+ CD8^+ T cells				CD4^+/CD8^+ T cell ratio
		Trials	Cases	SMD(95% CI)	I^2	Trials	Cases	SMD(95% CI)	I^2	Trials	Cases	SMD(95% CI)	I^2	Trials	Cases	SMD(95% CI)	I^2
Totality	REM	23	1888	1.85 [1.39, 2.31]	94%	23	1889	0.87 [0.65, 1.10]	81%	26	2066	1.04 [0.58, 1.50]	96%	14	1008	0.75 [0.27, 1.22]	92%
(a) Subgroup analysis via DC-CIK types (Figure S1–4)
DC-CIK cells	REM	17	1195	2.21 [1.64, 2.78]	94%	17	1196	0.99 [0.68, 1.31]	85%	20	1373	1.32 [0.72, 1.91]	96%	12	827	0.84 [0.28, 1.40]	93%
Ag-DC-CIK cells	REM	6	693	0.88 [0.11, 1.65]	95%	6	693	0.57 [0.41, 0.72]	0%	6	693	0.18 [−0.56, 0.92]	95%	2	181	0.25 [−0.05, 0.54]	0%
(b) Subgroup analysis via treatment cycles (Figure S5–8)
One cycle	REM	9	821	1.16 [0.59, 1.74]	92%	9	821	0.70 [0.42, 0.98]	70%	10	868	0.64 [0.05, 1.23]	94%	5	327	0.86 [0.33, 1.38]	81%
Two cycles	REM	6	464	1.51 [0.88, 2.13]	89%	7	536	0.87 [0.50, 1.23]	75%	8	601	0.57 [−0.12, 1.27]	94%	4	272	1.27 [0.90, 1.65]	51%
Three cycles	REM	2	124	2.83 [1.05, 4.60]	91%	2	139	2.07 [1.63, 2.51]	9%	2	139	2.47 [1.87, 3.08]	43%	No	No	No	No
Four cycles	REM	2	122	4.36 [3.69, 5.03]	0%	2	122	1.07 [0.62, 1.52]	25%	3	187	2.00 [−0.11, 4.11]	97%	1	52	−0.58 [−1.14, −0.03]	No
Six cycles	REM	1	100	2.41 [1.89, 2.93]	No	1	100	−0.03 [−0.42, 0.36]	No	1	100	6.04 [5.10, 6.98]	No	1	100	−1.16 [−1.58, −0.73]	No
Two to six cycles	REM	2	137	3.43 [2.89, 3.96]	0%	1	51	1.05 [0.46, 1.64]	No	1	51	0.15 [−0.40, 0.70]	No	2	137	1.23 [−0.22, 2.68]	93%
Unclear	REM	1	120	0.05 [−0.31, 0.40]	No	1	120	0.58 [0.21, 0.95]	No	1	120	−0.33 [−0.69, 0.03]	No	1	120	0.35 [−0.01, 0.71]	No
(c) Subgroup analysis via combination with chemotherapy (Figure S9–12)
Taxanes	REM	7	504	1.80 [0.81, 2.79]	95%	8	591	1.03 [0.44, 1.62]	91%	9	656	1.87 [0.86, 2.88]	97%	4	285	0.28 [−0.89, 1.46]	95%
NP	REM	5	349	2.34 [1.54, 3.15]	88%	5	349	0.92 [0.52, 1.32]	68%	6	414	1.34 [0.22, 2.47]	96%	3	200	1.20 [0.71, 1.69]	62%
GP	REM	5	343	1.75 [0.58, 2.93]	95%	4	257	0.73 [0.19, 1.26]	77%	4	257	−0.28 [−0.61, 0.05]	44%	4	283	1.29 [0.58, 2.00]	86%
Pemetrexed	REM	2	172	3.14 [0.03, 6.26]	96%	2	172	0.90 [0.14, 1.67]	79%	3	219	1.12 [0.57, 1.68]	69%	1	52	−0.58 [−1.14, −0.03]
Systemic	REM	4	520	0.91 [−0.05, 1.87]	96%	4	520	0.61 [0.44, 0.79]	0%	4	520	0.08 [−0.92, 1.08]	96%	2	188	0.54 [0.11, 0.96]	49%

Note: REM: random-effects model; SMD: standardized mean difference; SM: statistical method; taxanes: taxane chemotherapy as paclitaxel and cisplatin (TP), paclitaxel and nedaplatin (TN), and docetaxel and cisplatin (DP); NP: navebine and cisplatin; GP: gemcitabine and cisplatin; pemetrexed: pemetrexed chemotherapy including pemetrexed and cisplatin and pemetrexed alone; systemic: systemic chemotherapy including GP, TP, DP, et al.